Power Law company profile

Provention Bio

Biotech & Life Sciences · Lebanon, United States · Founded 2016 · IPO 2018 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$2.16B

Market cap · 2026

Revenue

$13M

Latest reported FY

Investors

3 investors on Provention Bio's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 3 investors entered at this stage

Johnson & Johnson Innovation

JDRF T1D Fund

MDB Capital Group

Global footprint

Where Provention Bio has talent and traffic

Web traffic by country

80 monthly visits
across markets

🇬🇧 United Kingdom125%

Top 1 markets shown

Patent intelligence

$4M patent portfolio · 22 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$4M

0.19% of market cap · 128.3× smaller than top peer ChemoCentryx ($524M)

22 active patent families

Where Provention Bio innovates CD3 AntibodyPharmacologyType 1 diabetesClinical typeAntiendomysial antibodies

Tech-focus vs peers

Where Provention Bio concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Provention Bio and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Provention Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo